Urgent.News

What's breaking now, across thousands of outlets.

AI

The Download: AI’s extinction risk and bioweapons threat

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Could AI really kill us all? Your questions, answered On Wednesday, MIT Technology Review hosted a live Roundtables event that asked the question many seem to be asking right now: could…

The Download: AI’s extinction risk and bioweapons threat

This weekly newsletter, The Download, provides a daily dose of news related to the technology world. Recently, MIT Technology Review hosted a live Roundtables event to discuss the potential for artificial intelligence to wipe out humanity entirely. The event saw the participation of senior AI editor Will Douglas Heaven and AI reporter Grace Huckins who attempted to answer the multitude of questions raised by the audience.

Some of the topics covered in the discussion include: the likelihood of AI causing human extinction, the underlying reasons behind such a possibility, and the extent to which AI is actually dangerous or if it's merely a tool for companies to generate publicity. To fully understand the issues surrounding AI and its potential for destruction, please read the full newsletter provided by The Download.

Written by urgent.news from MIT Technology Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at technologyreview.com →

More in AI

London-based Big Picture Bio emerges from stealth with €2.55 million to develop AI-designed cancer drug combinations

Big Picture Bio, a London-based BioTech startup developing AI-designed combination therapies for cancer and other complex diseases, has emerged from stealth with a combined funding round of €2.55…

  • London-based Big Picture Bio exits stealth with €2.55M funding
  • €1.75M pre-Seed round led by Kadmos Capital and Exceptional Ventures
  • AI models predict 12 successful cancer drug combos ahead of ASCO 2026

More from Friday 18 September →